• Je něco špatně v tomto záznamu ?

Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs

C. Schmidt, T. Babu, H. Kostrhunova, A. Timm, U. Basu, I. Ott, V. Gandin, V. Brabec, D. Gibson

. 2021 ; 64 (15) : 11364-11378. [pub] 20210803

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004976

"Multi-action" Pt(IV) derivatives of cisplatin with combretastatin A4 (CA4) bioactive ligands that are conjugated to Pt(IV) by carbonate are unique because the ligand (IC50 < 10 nM) is dramatically 1000-folds more cytotoxic than cisplatin in vitro. The Pt(IV)-CA4 prodrugs were as cytotoxic as CA4 itself, indicating that the platinum moiety probably plays an insignificant role in triggering cytotoxicity, suggesting that the Pt(IV)-CA4 complexes act as prodrugs for CA4 rather than as true multi-action prodrugs. In vivo tests (Lewis lung carcinoma) show that ctc-[Pt(NH3)2(PhB)(CA4)Cl2] inhibited tumor growth by 93% compared to CA4 (67%), cisplatin (84%), and 1:1:1 cisplatin/CA4/PhB (85%) while displaying <5% body weight loss compared to cisplatin (20%) or CA4 (10%). In this case, and perhaps with other extremely potent bioactive ligands, platinum(IV) acts merely as a self-immolative carrier triggered by reduction in the cancer cell with only a minor contribution to cytotoxicity.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004976
003      
CZ-PrNML
005      
20230425171829.0
007      
ta
008      
230418s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.jmedchem.1c00706 $2 doi
035    __
$a (PubMed)34342437
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Schmidt, Claudia $u Institute for Drug Research, School of Pharmacy, The Hebrew University, 91120 Jerusalem, Israel
245    10
$a Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs / $c C. Schmidt, T. Babu, H. Kostrhunova, A. Timm, U. Basu, I. Ott, V. Gandin, V. Brabec, D. Gibson
520    9_
$a "Multi-action" Pt(IV) derivatives of cisplatin with combretastatin A4 (CA4) bioactive ligands that are conjugated to Pt(IV) by carbonate are unique because the ligand (IC50 < 10 nM) is dramatically 1000-folds more cytotoxic than cisplatin in vitro. The Pt(IV)-CA4 prodrugs were as cytotoxic as CA4 itself, indicating that the platinum moiety probably plays an insignificant role in triggering cytotoxicity, suggesting that the Pt(IV)-CA4 complexes act as prodrugs for CA4 rather than as true multi-action prodrugs. In vivo tests (Lewis lung carcinoma) show that ctc-[Pt(NH3)2(PhB)(CA4)Cl2] inhibited tumor growth by 93% compared to CA4 (67%), cisplatin (84%), and 1:1:1 cisplatin/CA4/PhB (85%) while displaying <5% body weight loss compared to cisplatin (20%) or CA4 (10%). In this case, and perhaps with other extremely potent bioactive ligands, platinum(IV) acts merely as a self-immolative carrier triggered by reduction in the cancer cell with only a minor contribution to cytotoxicity.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x chemická syntéza $x chemie $x farmakologie $7 D000970
650    _2
$a karboanhydrasa IV $x chemie $x metabolismus $7 D030741
650    _2
$a buněčné linie $7 D002460
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a Cricetulus $7 D003412
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a lidé $7 D006801
650    _2
$a ligandy $7 D008024
650    _2
$a molekulární struktura $7 D015394
650    _2
$a organoplatinové sloučeniny $x chemická syntéza $x chemie $x farmakologie $7 D009944
650    _2
$a prekurzory léčiv $x chemická syntéza $x chemie $x farmakologie $7 D011355
650    _2
$a prohibitiny $7 D000091402
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Babu, Tomer $u Institute for Drug Research, School of Pharmacy, The Hebrew University, 91120 Jerusalem, Israel
700    1_
$a Kostrhunova, Hana $u Institute of Biophysics, Czech Academy of Sciences, Academy of Sciences, Kralovopolska 135, 61265 Brno, Czech Republic
700    1_
$a Timm, Annika $u Institute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Beethovenstrasse 55, 38106 Braunschweig, Germany
700    1_
$a Basu, Uttara $u Institute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Beethovenstrasse 55, 38106 Braunschweig, Germany
700    1_
$a Ott, Ingo $u Institute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Beethovenstrasse 55, 38106 Braunschweig, Germany
700    1_
$a Gandin, Valentina $u Dipartimento di Scienze del Farmaco, Universita di Padova, Via Marzolo 5, 35131 Padova, Italy
700    1_
$a Brabec, Viktor $u Institute of Biophysics, Czech Academy of Sciences, Academy of Sciences, Kralovopolska 135, 61265 Brno, Czech Republic $u Department of Biophysics, Faculty of Science, Palacky University in Olomouc, Slechtitelu 27, 78371 Olomouc, Czech Republic $1 https://orcid.org/0000000282331393 $7 jo20010087133
700    1_
$a Gibson, Dan $u Institute for Drug Research, School of Pharmacy, The Hebrew University, 91120 Jerusalem, Israel $1 https://orcid.org/0000000216314018
773    0_
$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 64, č. 15 (2021), s. 11364-11378
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34342437 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171825 $b ABA008
999    __
$a ok $b bmc $g 1925208 $s 1191185
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2021 $b 64 $c 15 $d 11364-11378 $e 20210803 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace